Arcutis Biotherapeutics, Inc. 4

Insider Howard G. Welgus exercised options to acquire 4,096 Arcutis Biotherapeutics (ARQT) shares and sold 4,730 shares at $26.91 on July 15, 2026 under a 10b5-1 plan.

On July 15, 2026, insider Howard G. Welgus of Arcutis Biotherapeutics, Inc. exercised three tranches of stock options to acquire a total of 4,096 shares of common stock at exercise prices of $6.5223, $7.51, and $8.63 per share, and on the same date sold 4,730 shares of common stock at $26.91 per share pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2026. The option exercises were reported as acquisitions of 822, 1,019, and 2,255 shares, respectively, increasing his common stock holdings before the subsequent sale, while the sale reduced his position to 37,109 shares of common stock held directly after the transactions. The options exercised were fully vested and carried expiration dates in 2029, 2033, and 2034, and following these transactions the corresponding option positions were reduced by 822, 1,019, and 2,255 underlying shares, respectively.

Filing Facts

CIK

1787306

Ticker

ARQT

Form

4

Source Type

fda

Accession

0001628280-26-048641

Alert Tier

6